Navigation Links
BioMS Medical recognized at Scrip Awards 2008
Date:12/11/2008

Toronto Stock Exchange Symbol: MS

EDMONTON, Dec. 11 /PRNewswire-FirstCall/ - BioMS Medical Corp (TSX: MS), a leading developer in the treatment of multiple sclerosis (MS), today announced that the Company was the recipient of the "Licensing Deal of the Year Award" at the 4th Annual Scrip Awards held in London, U.K. In December 2007, BioMS entered into a licensing and development agreement granting Eli Lilly and Company (Lilly) exclusive worldwide rights to dirucotide, for the treatment of MS, in exchange for an US$87 million upfront payment, potential development and sales milestones up to US$410 million and escalating royalties on sales.

"We are honored to receive this award which recognizes the significance of the alliance between BioMS and our partner Lilly," said Kevin Giese, President and CEO of BioMS Medical. "This partnership demonstrates a mutual commitment focused on developing an effective therapeutic option for patients with secondary progressive MS, a debilitating disease of global proportion for which there are limited treatment options."

    About The Scrip Awards 2008
    ---------------------------

The Scrip Awards, hosted by Informa Healthcare - one of the world's leading medical and scientific publishers - brings together hundreds of senior-level industry experts at one of the industry's most prestigious and hotly contested awards ceremony, to highlight the achievements of pharmaceutical companies throughout the year. For further information visit http://scripawards.com.

    About BioMS Medical Corp.
    -------------------------

BioMS Medical is a Canadian biotech company engaged in the development and commercialization of novel therapeutic technologies. BioMS Medical's lead technology, dirucotide (MBP8298), is for the treatment of multiple sclerosis and is being evaluated in two pivot
'/>"/>

SOURCE BioMS Medical Corp.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. BioMS Medical announces its intention to renew a normal course issuer bid
2. BioMS Medical to present at BioContact 2007
3. BioMS Medicals relapsing-remitting multiple sclerosis trial receives positive review from Data Safety Monitoring Board
4. BioMS Medical achieves enrollment milestone in U.S. phase III multiple sclerosis trial
5. BioMS Medical announces third quarter 2007 results
6. BioMS Medicals phase III U.S. multiple sclerosis trial receives positive safety review from Data Safety Monitoring Board
7. BioMS Medicals pivotal international multiple sclerosis trial receives positive review from Data Safety Monitoring Board
8. Lilly and BioMS Medical Announce Global Licensing and Development Agreement
9. BioMS Medical to present at BIO CEO & Investor Conference
10. BioMS Medical Announces 2007 Year End Results
11. BioMS Medical to present at BioCentury Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/29/2015)... Sanofi, un leader mondial ... pour le premier semestre 2015. Le Directeur Général ... Visionner l,interview vidéo et lire la transcription ... Au sommaire de l,interview :  - ... - Diabète - Praluent ...
(Date:7/29/2015)... , July 29, 2015 /PRNewswire/ - BioAmber Inc. (NYSE: ... , the Company,s Chief Financial Officer has resigned.  The ... Chief Financial Officer who retired in December 2014, as ... for a permanent successor.     Andy Ashworth ... Laurin and ensure a smooth transition.  Andy was the ...
(Date:7/29/2015)... 29, 2015 Research ... addition of the "Global Biosimilars Market, 2015 ... The Global Biosimilars Market, 2015 - 2025, ... growing biosimilars market. With the blockbuster biologics losing ... costs, biosimilars are being viewed as viable substitutes ...
(Date:7/29/2015)... July 29, 2015  Pfenex Inc. (NYSE MKT: PFNX) ... will be released on Thursday, August 13, 2015, before ... Pfenex management will host a conference call to discuss ... press release outlining the financial results and business update ... Please call 1-866-376-8058 (US) or 1-412-542-4131 (international) and ...
Breaking Biology Technology:BioAmber Announces Change in Chief Financial Officer 2BioAmber Announces Change in Chief Financial Officer 3Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 2Global Biosimilars Market to 2025: Monoclonal Antibodies (mAbs), Insulin, Interferons, G-CSF/ GM-CSF, Erythropoietins and Others 3Pfenex To Report Second Quarter 2015 Results and Provide Business Update on Thursday, August 13, 2015 2
... Divine Skin (OTC Bulletin Board: DSKX ) has ... its diverse consumer goods business and accelerate development through its ... RECORD 2010 REVENUE.  Divine Skin started the ... $1.9 million or 55 percent over 2009. ...
...  MedTRACK, an Informa business unit, and the world,s ... unveiled a premier partnering tool for the J.P. ... attending the conference find licensing, investment and acquisition ... Filter companies can quickly identify like-minded suitors in ...
... a privately held biotechnology company that develops next ... receive a milestone payment from Boehringer Ingelheim.  The ... agreement executed in October 2010 to discover, develop ... Re-Targeting (DART) platform.  The amount of the milestone ...
Cached Biology Technology:Another Successful Year at Divine Skin 2Another Successful Year at Divine Skin 3MedTRACK Unveils Partnering Tool for J.P. Morgan Healthcare Conference 2MacroGenics Receives Milestone Payment as Part of Its Global DART™ Alliance with Boehringer Ingelheim 2
(Date:7/27/2015)... , July 27, 2015  Synaptics Inc. (NASDAQ: ... interface solutions, today announced that Huawei has selected ... solution for its stylish smartwatch. Huawei chose the ... reliability, low power and highly responsive human interface ... Huawei designers also required a classic round watch ...
(Date:7/21/2015)... July 21, 2015  NXT-ID, Inc. (NASDAQ: ... authentication company focused on the growing mobile commerce ... announces that it has filed provisional patent 62/192218 ... This invention highlights next generation ... an account, but also the user using unique ...
(Date:7/9/2015)... JOSE, Calif. , July 9, 2015  Synaptics ... interface solutions, announced today that it will report financial ... on Thursday, July 30, 2015 after the close of ... for analysts and investors at 2:00 p.m. PT (5:00 ...   To participate on the live call, ...
Breaking Biology News(10 mins):Synaptics Touchscreen Solution Powers New Huawei Watch 2Synaptics Touchscreen Solution Powers New Huawei Watch 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 2NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 3NXT-ID Patents Personalized Tokenized Payments for Next Generation Secure Payment Technology 4Synaptics to Report Fourth Quarter, Fiscal Year 2015 Results on July 30 2
... Every creature has its place and role in the oceans ... may lead to more accurate models of ocean change. , ... niche for most animals and plants ?a shark, for example, ... have been relegated to an also-ran world of "functional redundancy" ...
... a rare disease in which patients develop multiple, benign skin ... throughout the body, according to a report in the May ... from the loss of a gene called CYLD, causing tumors ... indicated a role for CYLD in inflammation, but the mechanism ...
... When a faulty protein wreaks havoc in cells and ... finger at a wayward gene. Now scientists are learning ... gene is perfectly normal. The diseases can be caused ... not executed properly, leading to a lethal buildup of ...
Cached Biology News:Bacteria can help predict ocean change 2Gene first linked to rare disease may trigger skin cancer, other tumors 2Gene first linked to rare disease may trigger skin cancer, other tumors 3'Sticky' mice lead to discovery of new cause of neurodegenerative disease 2'Sticky' mice lead to discovery of new cause of neurodegenerative disease 3'Sticky' mice lead to discovery of new cause of neurodegenerative disease 4
Request Info...
Agarose-LE, 500 g. Suitable for soft agarose cloning. Nuclease-free.Gel point (1.5%): 36 1.5 C, EEO (-mr): 1200 g/cm2. Category: Nucleotides & Enzymes & Biochemicals, Ultrapure Biochemicals ....
Request Info...
Request Info...
Biology Products: